Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

3-Iodobenzylguanidine 3cabozantinib 2pembrolizumab 1pazopanib 1lutetium Lu 177 dotatate 1guadecitabine 1gallium Ga 68 dotatate 1copper dotatate CU-64 1atezolizumab 1Sunitinib 1Radiosurgery 1Phenoxybenzamine 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Iodine-131 1Everolimus 1Erlotinib Hydrochloride 1Doxazosin 1Axitinib 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Paraganglioma × Lutetium-177 × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡